AOLS Insider Trading Activity and SEC Form 4 Filings
AOLS insider trading summary
No open-market insider purchases or sales of Aeolus Pharmaceuticals, Inc. (AOLS) have been reported on SEC Form 4 in the past 12 months.
Latest AOLS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 6, 2013 | John L McManus | President and CEO | Buy | $4K (10,000 @ $0.35) |
| Feb 19, 2013 | Joseph J Krivulka | Director | Buy | $0 (400,000 @ $0.00) |
| Feb 19, 2013 | Xmark Opportunity Partners, LLC | 10% Owner | Sell | $592K (1,793,894 @ $0.33) |
| May 23, 2012 | Russell Skibsted | Chief Financial Officer | Buy | $2K (7,027 @ $0.24) |
| Apr 5, 2012 | Joseph J Krivulka | Director | Buy | $100K (333,333 @ $0.30) |
| May 24, 2011 | John L McManus | President and CEO | Buy | $5K (10,000 @ $0.45) |
| May 24, 2011 | John L McManus | President and CEO | Buy | $141 (300 @ $0.47) |
| May 18, 2011 | John L McManus | President and CEO | Buy | $4K (10,000 @ $0.43) |
| May 18, 2011 | Russell Skibsted | Chief Financial Officer | Buy | $2K (5,000 @ $0.42) |
| May 18, 2011 | John L McManus | President and CEO | Buy | $4K (10,000 @ $0.43) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.